Key Highlights
- Blue Wolf Capital acquires seven European facilities from Recipharm, specializing in oral solid, semi-solid, and liquid dosage pharmaceutical products.
- The acquisition supports Blue Wolf’s goal to build an industry-leading CDMO platform.
- Blue Wolf also plans to acquire Synerlab, a CDMO in France and Spain, pending regulatory approval.
- Bruce Vielle will serve as CEO of the combined organization, supported by a team of industry experts.
Source: Business Wire
Notable Quotes
- “By honoring both cultures, we will create an even stronger and more exciting one to serve our customers and patients.” — Bruce Vielle, Chief Executive Officer at Synerlab
- “We see significant growth potential in these facilities and look forward to building a best-in-class CDMO focused on delivering outstanding service and high-quality pharmaceutical products.” — Shashank Patel, Principal at Blue Wolf
SoHC's Take
This acquisition marks a significant milestone for Blue Wolf Capital, as it not only strengthens its presence in the pharmaceutical manufacturing space but also underscores its commitment to building a leading CDMO platform in Europe. With a highly experienced leadership team at the helm and the strategic acquisition of Synerlab, Blue Wolf is well-positioned to capitalize on market demand and regulatory compliance for high-quality pharmaceutical products. The anticipated growth of this combined platform will likely enhance its market reach across Europe and beyond, contributing to its long-term success.
